Cabaletta Bio Reports Q3 2024 Financial Results

TipRanksNov 18 22:54 ET

Express News | Cabaletta Bio Announces Presentation Of Updated CABA-201 Clinical Data At ACR Convergence 2024l; Says Safety Profile Suggested Favorable Risk-Benefit With No CRS Or ICANS In Majority Of Patients

BenzingaNov 18 07:22 ET

Cabaletta Bio's CABA-201 Shows Results in Autoimmune Disease Trials

BenzingaNov 18 07:11 ET

William Blair Maintains Cabaletta Bio(CABA.US) With Buy Rating

Moomoo NewsNov 18 04:33 ET · Ratings

Cabaletta Bio Is Maintained at Overweight by Wells Fargo

Dow JonesNov 15 14:23 ET · Ratings

H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $25

Moomoo NewsNov 15 11:32 ET · Ratings